Cader, Fathima Zumla http://orcid.org/0000-0001-5107-0146
Hu, Xihao http://orcid.org/0000-0002-3517-6351
Goh, Walter L.
Wienand, Kirsty
Ouyang, Jing
Mandato, Elisa
Redd, Robert http://orcid.org/0000-0002-1329-5288
Lawton, Lee N.
Chen, Pei-Hsuan
Weirather, Jason L. http://orcid.org/0000-0003-0556-0616
Schackmann, Ron C. J.
Li, Bo http://orcid.org/0000-0002-8617-900X
Ma, Wenjiang
Armand, Philippe http://orcid.org/0000-0001-6098-1603
Rodig, Scott J.
Neuberg, Donna http://orcid.org/0000-0003-2566-3145
Liu, X. Shirley http://orcid.org/0000-0003-4736-7339
Shipp, Margaret A. http://orcid.org/0000-0002-3949-6897
Article History
Received: 21 November 2019
Accepted: 1 July 2020
First Online: 10 August 2020
Competing interests
: After completing the current studies at DFCI, F.Z.C. and X.H. became full-time employees at Astra Zeneca and GV20, respectively. P.A. consults for Merck, Bristol Myers Squibb (BMS), Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics and Celgene and receives institutional research funding from Merck, BMS, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma Tau, Genentech and IGM and honoraria from Merck and BMS. S.J.R. has received research funding from BMS, Merck, Affimed and Kite/Gilead. X.S.L. is a cofounder and board member of GV20 Oncotherapy, SAB of 3DMedCare, consultant for Genentech, and stockholder of BMY, TMO, WBA, ABT, ABBV, and JNJ. X.S.L. has received funding from Takeda and Sanofi. M.A.S. has received research funding from BMS, Merck and Bayer and has served on advisory boards for BMS and Celgene. The remaining authors declare no competing financial interests.